GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis
Cancer Immunology, Immunotherapy · 04.08.2025 · 74 (9)
DOI: 10.1007/s00262-025-04133-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.08.2025. Verfasst von Marta Kłopotowska und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 5 Adolfa Pawinskiego St., 02-106, Warsaw, Poland. Hauptthemen laut MEDLINE: Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Warszawski Uniwersytet Medyczny, Polish Ministry of Science and Higher Education, HORIZON EUROPE European Research Council.
Abstract (Originalsprache)
Induction of ferroptosis, an iron-dependent form of regulated cell death, holds promise as a strategy to overcome tumor resistance to conventional therapies and enhance immunotherapy responses. However, while the susceptibility of tumor cells to ferroptosis is extensively studied, limited data exists on the vulnerability of immune cells to disturbed iron balance and lipid peroxidation. Here, we found that T-cell stimulation rewires iron and redox homeostasis and by increasing levels of reactive oxygen species and labile iron promotes lipid peroxidation and T-cells’ ferroptosis. Upon stimulation, we detected changes in the balance of ferroptosis-suppressive proteins, including decrease of GPX4. Subsequently, we identified GPX4 as a master regulator orchestrating T/CAR-T-cells’ sensitivity to ferroptosis and observed that GPX4 inhibitors impair CAR-T cells’ antitumor functions. Our study demonstrated differential GPX4 expression and diverse susceptibility to ferroptosis between CD4⁺ and CD8⁺ T cells. Among analyzed subsets of naïve, central memory (CM), effector memory (EM), and terminally differentiated effector memory (TEMRA), CD8⁺ EM and CD8⁺ TEMRA cells exhibited the highest sensitivity to ferroptosis. We also showed that ferroptosis limited the anti-tumor efficacy of CAR-T cells, while ferroptosis inhibition improved their therapeutic effect, both in vitro and in vivo. Our findings are not only important to understand vulnerabilities of CAR-T cells but may also hold particular significance for their therapeutic development. In this context, future anticancer therapies should be carefully designed to selectively induce the ferroptosis of tumor cells without impeding cytotoxic cells’ antitumor efficacy. Additionally, we postulate that promoting less differentiated phenotype of CAR-T cells should be exploited therapeutically to create CAR-T products characterized by decreased sensitivity to ferroptosis within tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 5 Adolfa Pawinskiego St., 02-106, Warsaw, Poland.
- Immunooncology Students' Science Association, Medical University of Warsaw, Warsaw, Poland.
- Department of Immunology, Medical University of Warsaw, 5 Jana Nielubowicza St., 02-097, Warsaw, Poland.
- Doctoral School, Medical University of Warsaw, 81 Zwirki i Wigury St., 02-091, Warsaw, Poland.
- Department of Bacteriology and Biocontamination Control, National Institute of Public Health NIH-National Research Institute, 24 Chocimska St., 00-791, Warsaw, Poland.
- Centre for Advanced Materials and Technologies, Warsaw University of Technology, 19 Poleczki St., 02-822, Warsaw, Poland.
Förderung
- Warszawski Uniwersytet Medyczny
- Polish Ministry of Science and Higher Education
- HORIZON EUROPE European Research Council
- Narodowe Centrum Nauki
Zitieren
APA
Kłopotowska, M., Baranowska, I., Hajduk, S., Jurga, A., Leśniowska, N., Łaźniewski, M., Granica, M., Krawczyk, M., Dziewicka, M., Graczyk, A., Słupski, J., Zagożdżon, R., Plewczynski, D., Winiarska, M., & Bajor, M. (2025). GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis. Cancer Immunology, Immunotherapy, 74(9). https://doi.org/10.1007/s00262-025-04133-w
Vancouver
Kłopotowska M, Baranowska I, Hajduk S, Jurga A, Leśniowska N, Łaźniewski M, et al. GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis. Cancer Immunology, Immunotherapy. 2025;74(9). doi:10.1007/s00262-025-04133-w
BibTeX
@article{Kopotowska2025,
author = {Kłopotowska, Marta and Baranowska, Iwona and Hajduk, Szymon and Jurga, Anna and Leśniowska, Natalia and Łaźniewski, Michał and Granica, Monika and Krawczyk, Marta and Dziewicka, Milena and Graczyk, Agnieszka and Słupski, Jan and Zagożdżon, Radosław and Plewczynski, Dariusz and Winiarska, Magdalena and Bajor, Malgorzata},
title = {GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {9},
doi = {10.1007/s00262-025-04133-w}
}
EUVIMED